Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cance...

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patien...

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-
Clinical Trials
Related News

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer

First Posted Date
2024-05-08
Last Posted Date
2024-05-08
Lead Sponsor
Fudan University
Target Recruit Count
76
Registration Number
NCT06404463

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

First Posted Date
2024-05-06
Last Posted Date
2024-12-20
Lead Sponsor
Children's Oncology Group
Target Recruit Count
1656
Registration Number
NCT06401330

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

First Posted Date
2024-04-30
Last Posted Date
2024-12-16
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
145
Registration Number
NCT06390319
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

First Posted Date
2024-04-29
Last Posted Date
2024-05-23
Lead Sponsor
RemeGen Co., Ltd.
Target Recruit Count
79
Registration Number
NCT06389006
Locations
🇨🇳

Jiong Wu, Shanghai, Fudan University Shanghai Cancer Center, China

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL

First Posted Date
2024-04-26
Last Posted Date
2024-04-26
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
53
Registration Number
NCT06387121

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

First Posted Date
2024-04-25
Last Posted Date
2024-11-20
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
54
Registration Number
NCT06383572
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

A Phase 1 Study of ADI-001 in Lupus Nephritis

First Posted Date
2024-04-19
Last Posted Date
2024-10-31
Lead Sponsor
Adicet Therapeutics
Target Recruit Count
40
Registration Number
NCT06375993
Locations
🇺🇸

The Feinstein Institutes for Medical Research - Northwell Health, Manhasset, New York, United States

A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus

First Posted Date
2024-04-18
Last Posted Date
2024-06-17
Lead Sponsor
EdiGene Inc.
Target Recruit Count
12
Registration Number
NCT06373991
Locations
🇨🇳

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China

Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)

First Posted Date
2024-04-16
Last Posted Date
2024-04-19
Lead Sponsor
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Target Recruit Count
50
Registration Number
NCT06367114
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Suzhou, China

🇨🇳

Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd., Shanghai, Shanghai, China

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

First Posted Date
2024-04-15
Last Posted Date
2024-12-03
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
66
Registration Number
NCT06364423
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy